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Health & Services
The purpose of this study is to identify intervention 
strategies to improve the statin metric for secondary 
prevention among patients with clinical 
atherosclerotic cardiovascular disease (ASCVD) in 
the primary care setting at Providence Medical 
Group (PMG). 
• Per the Centers for Disease and Control 
Prevention, cardiovascular disease is the leading 
cause of morbidity and mortality in United States. 
Nearly one in three American dies of stroke or 
heart disease. 
• According to the 2018 American College of 
Cardiology/American Heart Association guideline, 
high-intensity statin therapy or maximally tolerated 
statin therapy is recommended for patients with 
clinical ASCVD. 
• Common barriers for initiating statin therapy 
include previous intolerance or side effects, lack of 
perceived benefits versus risks, and financial 
burden.
• Currently, there is a gap in meeting the statin 
metric in PMG Southern Oregon region.
• As of October 2019, 667 patients were identified 
as either not being prescribed statin therapy or not 
on optimized statin therapy among 8 clinics in the
PMG Southern Oregon region. 
1. Centers for Disease Control and Prevention. Prescription cholesterol-
lowering medication use in adults aged 40 and over: United States 2003-
2012. Accessed October 22, 2019.
2. 2018 ACC/AHA Guideline on the Management of Blood Cholesterol. 
J Am Coll Cardiol. doi: 10.1016/j.jacc.2018.11.003
3. Dixon DL, Bolick JP, Godishala LM, et al. Clinician’s Toolkit: A Guide to 
Medication and Lifestyle Adherence. National Lipid Association.
Available at: http://www.lipid.org/practicetools/tools/adherence. Accessed 
October 19, 2019. 
• Different strategies will be implemented at a 
single clinic, Central Point Family Medicine Clinic, 
in the Southern Oregon region to demonstrate 
metric improvement
Inclusion Criteria:
• Patients aged ≥ 18 years old with diagnosis of 
clinical ASCVD who are either not prescribed 
statin therapy or are prescribed sub-optimal statin 
therapy
Exclusion Criteria:
• Pregnant women and nursing mothers
Primary Endpoints:
• Impact of academic detailing intervention on 
perceived barriers on statin initiation or 
optimization via pre- and post-intervention 
surveys
• Percentage of approved recommendation from 
providers
Secondary Endpoint:
• Percentage of statins prescribed per each 
intervention strategy
Two interventions:
1. Academic detailing
• Pre- and post-surveys were collected to assess 
the effectiveness of the presentation given during 
providers meeting
2. Providing recommendations to provider 
• Chart review for patients who met inclusion 
criteria via Epic encounters
Intervention 2: Providing Recommendation to Providers
Pre/Post Survey
Academic Detailing
• Comparing pre- and post-surveys, there was an 
increased percentage of providers who are 
willing to re-challenge a different statin/lower 
dose for patient with documented statin 
intolerance
• Survey results showed changes in providers’ 
beliefs when comparing pre and post survey
• Slight decrease in provider belief that statins 
cause myopathy, liver injury, incidental diabetes, 
cognitive impairment and rhabdomyolysis
Limitations:
• Unable to observe the content of provider 
discussion with patients or frequency of shared 
decision making
Providing Recommendation to Providers
• Majority of recommendations were approved by 
providers. However, no specific intervention has 
proven to be the most effective at increasing 
statin initiation or optimization
• Very little changes were observed across all 
intervention strategy selected by PCP
Limitations:
• Providers’ engagement level is variable and may 
have a large impact on the results of the study
• Due to COVID-19, patients may cancel health 
maintenance appointments to limit health care 
exposure postponing statin discussions beyond 
the timeframe of the project
• Difficult to track changes in statin prescribing if 
PCP selects options to discuss therapy during 
upcoming visits (3-6 months out)
• Many referred patients were unreached thus 
making it challenging for pharmacist to follow-up 
appropriately
Questions Pre-survey (n=8) Post-survey (n=7)
If a patient has a documented intolerance 
to statin therapy in the past (e.g. 
myopathy, myalgia), how likely patient 
will be re-challenged with a different 
statin or at a lower dose for ASCVD 
secondary prevention?
Often: 38% Very often: 71%
Sometimes: 50% Sometimes: 14%
Indicate whether statins causes liver 
injury based on your experience and 
scientific literature 
Yes: 62% Yes: 57%
No: 38% No: 29%
Evidence not definitive/not sure: 0% Evidence not definitive/not sure: 14%
Indicate whether statins cause myopathy 
based on your experience and scientific 
literature 
Yes: 88% Yes: 71%
No: 0% No: 0%
Evidence not definitive/not sure: 12% Evidence not definitive/not sure: 29%
Indicate whether that statins cause 
rhabdomyolysis based on your 
experience and scientific literature 
Yes: 88% Yes: 71%
No: 12% No: 14%
Evidence not definitive/not sure: 0% Evidence not definitive/not sure: 14%
Indicate whether statins cause cognitive 
impairment based on your experience 
and scientific literature 
Yes: 25% Yes: 0%
No: 12% No: 29%
Evidence not definite/not sure: 62% Evidence not definitive/not sure: 72%
Indicate whether statins cause incident 
diabetes based on your experience and 
scientific literature 
Yes: 50% Yes: 29%
No: 25% No: 29%
Evidence not definitive/not sure: 25% Evidence not definitive/not sure: 43%
For ASCVD secondary prevention, how 
often (in percentage %) a statin needs to 
be discontinued (including drug holidays), 
given patient complaints of adverse 
medical events?
5-50% 10-15%
Baseline therapy status (n=35):
5% on sub-
optimal statin
7% had 
documented 
statin 
intolerance
3% not 
candidates for 
high intensity 
statin
20% not 
prescribed 
statin therapy
Results:
• 85.7% of all recommendations was approved by primary care providers 
(PCP)
• 51.4% of patients will discuss statin initiation and optimization in 
upcoming appointments with PCP. 
• 28.5% of patients received referral to clinical pharmacy services for 
ASCVD management
Percentage of statins prescribed per each intervention strategy:
Referral to clinical pharmacy for ASCVD collaborative management (n=10):
• One patient was successfully started in statin therapy via pharmacy 
management 
• 50% of patients declined statin initiation
• 40% of patients were unable to be reached
Discuss statin initiation/optimization in upcoming PCP appointments (n=18):
• No changes observed
• Propose to have statin assessment as part of 
annual health maintenance visits in the future for 
patients with clinical ASCVD
• Implement education tools like videos, handouts, 
or applications that can help to provide education 
and address concerns or questions on statin 
therapy
